Single Dose Study of MK-6482 in Healthy Japanese Female Participants

Phase 1

• Conditions: Renal Cell Carcinoma

• Registration Number: JPRN-jRCT2031220024
• Lead Sponsor: Tanaka Yoshiyuki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-16
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

Healthy female participants of nonchildbearing potential between the ages of 45 and 64 years

Exclusion Criteria

Has a history of clinically significant abnormalities or diseases

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pharmacokinetics (Cmax, Tmax, AUC0-last, AUC0-inf, CL/F, Vz/F and t1/2)

Secondary Outcome Measures

Name	Time	Method
Safety (Adverse events)